-
- EIB ta ba da lamuni Yuro miliyan 30 ga EryDel don haɓaka novel RBC maganin cututtukan da ba kasafai ba.
-
- Dandalin jiyya na EryDel da ke ƙarƙashin haɓaka don amfani da shi wajen magance cututtukan yara da ba kasafai ba kamar Ataxia Telangiectasia (AT).
-
- Tallafin kuɗi a ƙarƙashin Asusun Tarayyar Turai don Dabarun Zuba Jari, babban ɓangaren Tsarin Zuba Jari na Hukumar Turai don Turai.
Bankin Zuba Jari na Turai (EIB) da kamfanin fasahar kere-kere na Italiya EryDel SpA sun rattaba hannu kan kwangilar bayar da lamuni na Euro miliyan 30 ga EryDel. Wannan kamfani na zamani na zamani yana da niyyar haɓakawa da kasuwancin hanyoyin kwantar da hankali dangane da mallakarsa Fasahar RBC don maganin cututtukan da ba kasafai ba. Lamunin bankin EU yana goyan bayan garanti daga Asusun Turai don Dabarun Zuba Jari (EFSI), babban ginshiƙin Shirin Zuba Jari na Turai wanda EIB da Hukumar Tarayyar Turai ke aiki tare a matsayin abokan hulɗa mai mahimmanci, tare da ayyukan samar da kuɗin EIB na haɓaka gasa ga tattalin arzikin Turai.
Fasahar dandali na mallakar EryDel hanya ce mai sauƙi don amfani, sauri kuma ta atomatik don ɗaukar ƙanana da manyan ƙwayoyin cuta gami da enzymes na warkewa a cikin ƙwayoyin jajayen jinin marasa lafiya. Ana sake shigar da kwayoyin halitta nan da nan cikin marasa lafiya, suna samar da tsawon rabin rayuwa a wurare dabam dabam, rage yawan rigakafi, mafi kyawun haƙuri da rarrabawar jijiyoyin jini. Ana samar da samfuran EryDel mafi ci gaba don magance AT, cututtukan da ba safai ba ne na yara waɗanda ke haifar da nakasu mai tsanani. Za a yi amfani da fasahar RBC na dandalin EryDel don magance wasu cututtuka da ba kasafai ake samun su ba. Tallafin kuɗi zai goyi bayan R&D mai gudana ta kamfanin da hanyar sadarwar abokan hulɗa, wanda ya ƙunshi cibiyoyin bincike, cibiyoyin asibiti da ƙungiyoyin haƙuri.
Mataimakin shugaban EIB Dario Scannapieco sharhi: "Kasancewar EryDel yana haɓaka hanyoyin kwantar da hankali don cututtukan da ba kasafai ba shine dalilin da ya sa mu yi alfaharin tallafawa wannan yunƙurin.. Tare da goyan bayan EFSI, EIB na farin cikin ba da kuɗi don haɓaka EryDel na haɓakar aikin su na RBC mai sarrafa kansa don magance cututtukan yara masu tsanani. A matsayinmu na bankin Tarayyar Turai, dole ne mu tabbatar da cewa sabbin sabbin abubuwa EUKamfanoni masu tushe na ci gaba da samun kudaden shiga, ta yadda za su iya kawo fasahohinsu zuwa kasuwa don taimakawa wajen inganta rayuwar mutane."
Kwamishinan Tattalin Arziki na Turai, Paolo Gentiloni, ya ce:Shirin Zuba Jari don Turai yana da tasiri mai ƙarfi wajen ganowa da tallafawa kamfanonin fasaha masu ƙima. Tare da kuɗin kuɗin kamfanin EryDel na Italiya da fasaha na RBC na farko, za mu taimaka wajen tura iyakokin abin da zai yiwu a cikin maganin cututtuka masu wuyar gaske don amfanin marasa lafiya a Turai da kuma duniya baki daya.. "
EryDel CEO Luca Benatti ya ce:Mun yi farin cikin samun wannan tallafin daga EIB, wanda ke tallafawa hangen nesanmu na zama cikakken kamfani wanda zai iya kawo sabbin hanyoyin kwantar da hankali ga marasa lafiya. EIB a fili ya fahimci rashin biyan buƙatun likita don ingantattun hanyoyin kwantar da hankali ga cututtukan da ba kasafai ba da kuma yuwuwar taimaka wa marasa lafiya a Turai da ma duniya baki ɗaya, kuma suna goyan bayan imaninmu cewa nan gaba za a sami ingantattun hanyoyin kwantar da hankali da EryDel ya haɓaka don nau'ikan cututtukan da ba kasafai ba. . Za a yi amfani da kuɗaɗen ne don kashe kuɗin da aka tsara don bincike da haɓakawa da ayyukan kashe kuɗi. Yanzu da mun kammala rajista don gwajin asibiti na Mataki na 3 ATTeST, mafi girman binciken asibiti da aka taɓa gudanarwa a Ataxia Telangiectasia, tallafi da haɗin gwiwar da muke samu daga EIB yana da mahimmanci.. "
EryDel CCO Ronan Gannon ya ce:Muna da darajar samun EIB a matsayin abokin tarayya wanda ke raba ra'ayin kasuwanmu da hangen nesa na fasaha kuma ya amince da EryDel don taka muhimmiyar rawa a kasuwar cututtukan da ba kasafai ba ta duniya. Har ila yau, ya nuna cewa Turai tana taka muhimmiyar rawa a cikin manyan sababbin abubuwa. "
EryDel S.p.A. girma kamfani ne na duniya, na ƙarshen zamani wanda ke da niyyar yin amfani da fasahar sa na jan jini (RBC) don haɓakawa da kuma sayar da hanyoyin warkewa don maganin cututtukan da ba kasafai ba. Samfurin sa mafi ci gaba EryDex yana ƙarƙashin ci gaban ƙarshen zamani don maganin Ataxia Telangiectasia, cuta mai saurin kamuwa da ciwon kai wanda babu magani a halin yanzu. Gwajin gwaji na Mataki na II da aka kammala a cikin marasa lafiya na AT ya nuna ingancin ƙididdiga na EryDex akan duka ƙarshen farko da na biyu. A halin yanzu ana gudanar da nazari mai mahimmanci na mataki na uku na cibiyar ƙasa da ƙasa, ATTeST. EryDel yana da bututun shirye-shiryen asibiti na farko waɗanda ke aiki tare da fasahar isar da saƙon RBC na mallakar ta wajen magance wasu cututtukan da ba kasafai ba, wanda ya haɗa da amfani da magungunan maye gurbin enzyme.
